Scholarlink

Background/aim <p>Despite routine therapeutic drug monitoring after kidney transplantation, medication non-adherence often remains unrecognized until clinically relevant consequences become evident. This study aimed to assess medication adherence in kidney transplant recipients using self-reported measures and tacrolimus intra-patient variability (IPV), and to examine their association with graft function.</p> Materials and methods <p>This hybrid study combined a cross-sectional assessment of medication adherence with a prospective cohort follow-up. Tacrolimus trough concentrations, IPV, and estimated glomerular filtration rate (eGFR) were monitored over four consecutive routine visits (6–8 months). For each patient, eGFR was modelled as a function of time using simple linear regression, and the regression coefficient was used as the individual eGFR slope. Medication adherence was assessed using the BAASIS questionnaire. Associations between self-reported adherence, tacrolimus IPV (%CV), and graft function were analysed using the Mann–Whitney U and Kruskal–Wallis tests.</p> Results <p>More than half of the participants (31 patients, 54.4%) reported non-adherence, predominantly related to dosing-time deviations rather than missed doses. These deviations were associated with increased tacrolimus intra-patient variability. Patients with higher tacrolimus variability had lower mean eGFR during follow-up, although no significant differences in longitudinal eGFR decline were observed.</p> Conclusion <p>Increased tacrolimus IPV was associated with self-reported medication non-adherence, predominantly reflecting dosing-time deviations. Although these deviations did not result in a significantly faster decline in graft function during the 6–8-month follow-up, they increased tacrolimus variability, highlighting the importance of continued adherence monitoring to prevent greater variability and potential long-term adverse outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Hidden Non-Adherence to Tacrolimus after Kidney Transplantation: Insights from Self-Report and Intra-Patient Variability

  • 期刊论文

  • 发表日期：

    2026年7月22日

查看全文
  • Aleksandra Catić Đorđević,
  • Ana Kundalić,
  • Aleksandar Jovanović,
  • Anastasia Tsyplakova,
  • Branka Mitić,
  • Tatjana Cvetković,
  • Nikola Stefanović

摘要

Background/aim

Despite routine therapeutic drug monitoring after kidney transplantation, medication non-adherence often remains unrecognized until clinically relevant consequences become evident. This study aimed to assess medication adherence in kidney transplant recipients using self-reported measures and tacrolimus intra-patient variability (IPV), and to examine their association with graft function.

Materials and methods

This hybrid study combined a cross-sectional assessment of medication adherence with a prospective cohort follow-up. Tacrolimus trough concentrations, IPV, and estimated glomerular filtration rate (eGFR) were monitored over four consecutive routine visits (6–8 months). For each patient, eGFR was modelled as a function of time using simple linear regression, and the regression coefficient was used as the individual eGFR slope. Medication adherence was assessed using the BAASIS questionnaire. Associations between self-reported adherence, tacrolimus IPV (%CV), and graft function were analysed using the Mann–Whitney U and Kruskal–Wallis tests.

Results

More than half of the participants (31 patients, 54.4%) reported non-adherence, predominantly related to dosing-time deviations rather than missed doses. These deviations were associated with increased tacrolimus intra-patient variability. Patients with higher tacrolimus variability had lower mean eGFR during follow-up, although no significant differences in longitudinal eGFR decline were observed.

Conclusion

Increased tacrolimus IPV was associated with self-reported medication non-adherence, predominantly reflecting dosing-time deviations. Although these deviations did not result in a significantly faster decline in graft function during the 6–8-month follow-up, they increased tacrolimus variability, highlighting the importance of continued adherence monitoring to prevent greater variability and potential long-term adverse outcomes.